Literature DB >> 2849725

Chronic treatment with naltrexone enhances morphine-stimulated dopamine neurotransmission: neurochemical and behavioral evidence.

M T Bardo1, J L Neisewander, R B Ennis.   

Abstract

Rats were implanted for 10 days with a slow-release pellet of naltrexone or were given sham surgery. At one of various different intervals during or after implantation of the pellet, the synthesis of dopamine (DA) was assessed in the nigrostriatal and mesolimbic systems. The results indicated that naltrexone alone was without effect on the synthesis of DA. However, one day after removal of the pellet, naltrexone-treated animals displayed an enhanced response to the DA-stimulatory action of morphine (15 mg/kg) in both the nigrostriatal and mesolimbic systems. This change was accompanied by an increase in specific binding of the mu-specific radioligand [3H]DAGO in whole brain and by an increase in the depressant action of morphine on locomotor activity. In contrast, at 10 days after removal of the pellet, naltrexone was without effect on morphine-induced changes in the synthesis of DA and locomotor activity, thus indicating that the supersensitivity to morphine was transient. These results support the idea that opioids modulate DAergic neurotransmission in the nigrostriatal and mesolimbic pathways and that this modulatory role may underlie opiate-induced changes in locomotor behavior.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2849725     DOI: 10.1016/0028-3908(88)90004-4

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  6 in total

1.  Preparation of biodegradable microspheres and matrix devices containing naltrexone.

Authors:  Rassoul Dinarvand; Shadi H Moghadam; Leyla Mohammadyari-Fard; Fatemeh Atyabi
Journal:  AAPS PharmSciTech       Date:  2003       Impact factor: 3.246

2.  Increased sensitivity to rate-altering and discriminative stimulus effects of morphine following continuous exposure to naltrexone.

Authors:  A M Young; S R Mattox; M D Doty
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

3.  The effect of ketotifen in rodent models of anxiety and on the behavioural consequences of withdrawing from treatment with drugs of abuse.

Authors:  B Costall; M E Kelly; E S Onaivi; R J Naylor
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-06       Impact factor: 3.000

4.  Naltrexone maintenance fails to alter amphetamine effects on intracranial self-stimulation in rats.

Authors:  Farhana Sakloth; S Stevens Negus
Journal:  Exp Clin Psychopharmacol       Date:  2018-03-12       Impact factor: 3.157

5.  Pharmacological specificity of enhanced sensitivity to naltrexone in rats.

Authors:  C W Schindler; S R Goldberg; J L Katz
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

6.  Adenylyl cyclase type 5 (AC5) is an essential mediator of morphine action.

Authors:  Kyoung-Shim Kim; Ko-Woon Lee; Kang-Woo Lee; Joo-Young Im; Ji Yeoun Yoo; Seung-Woo Kim; Ja-Kyeong Lee; Eric J Nestler; Pyung-Lim Han
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-28       Impact factor: 11.205

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.